COMBINAISONS PHARMACEUTIQUES COMPRENANT UN INHIBITEUR D'HISTONE DÉSACÉTYLASE ET UN INHIBITEUR DU LIGAND DE MORT CELLULAIRE PROGRAMMÉE 1 (PD-L1) ET LEURS MÉTHODES D'UTILISATION
QUAYLE, Steven,JONES, Simon Stewart,HIDESHIMA, Teru,ANDERSON, Kenneth C.
申请号：
EP17873719
公开号：
EP3544600A4
申请日:
2017.11.21
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a programmed death ligand 1 (PD-L1) inhibitor, including combined preparations and pharmaceutical compositions thereof； uses of such combination in the treatment or prevention of cancer； and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
